Oruka Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
ORKA$109.50+4.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)
| Three Months Ended March 31, 2025 | Period from February 6, 2024 (Inception) to March 31, 2024 | |
|---|---|---|
| Operating expenses | ||
| Research and development (1) | $19,925 | $5,193 |
| General and administrative (2) | 5,161 | 1,670 |
| Total operating expenses | 25,086 | 6,863 |
| Loss from operations | (25,086) | (6,863) |
| Other income (expense) | ||
| Interest income | 4,092 | — |
| Interest expense (3) | — | (214) |
| Other expense, net | (5) | — |
| Total other income (expense), net | 4,087 | (214) |
| Net loss | (20,999) | (7,077) |
| Net change in unrealized gains (losses) on marketable securities | 35 | — |
| Comprehensive loss | $(20,964) | $(7,077) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.40) | $(2.21) |
| Net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted | $(32.95) | $— |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 41,679,560 | 3,197,977 |
| Weighted-average shares used in computing net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted | 137,138 | — |
| (1) | Includes related party amounts of $2,122 for the three months ended March 31, 2025 and $5,051 for the period from February 6, 2024 (inception) to March 31, 2024 |
| (2) | Includes related party amounts of $110 for the three months ended March 31, 2025 and $848 for the period from February 6, 2024 (inception) to March 31, 2024 |
| (3) | Includes related party amounts of nil for the three months ended March 31, 2025 and $214 for the period from February 6, 2024 (inception) to March 31, 2024 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.